{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:18:32Z","timestamp":1789705112684,"version":"4.0.1"},"reference-count":53,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T00:00:00Z","timestamp":1644624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["project: POWR.03.02.00-00-I051\/16; grant: 07\/IMSD\/G\/2019"],"award-info":[{"award-number":["project: POWR.03.02.00-00-I051\/16; grant: 07\/IMSD\/G\/2019"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>An effective strategy for successful chemotherapy relies on creating compounds with high selectivity against cancer cells compared to normal cells and relatively low cytotoxicity. One such approach is the discovery of critical points in cancer cells, i.e., where specific enzymes that are potential therapeutic targets are generated. Triazine is a six-membered heterocyclic ring compound with three nitrogen replacing carbon-hydrogen units in the benzene ring structure. The subject of this review is the symmetrical 1,3,5-triazine, known as s-triazine. 1,3,5-triazine is one of the oldest heterocyclic compounds available. Because of its low cost and high availability, it has attracted researcher attention for novel synthesis. s-Triazine has a weak base, it has much weaker resonance energy than benzene, therefore, nucleophilic substitution is preferred to electrophilic substitution. Heterocyclic bearing a symmetrical s-triazine core represents an interesting class of compounds possessing a wide spectrum of biological properties such as anti-cancer, antiviral, fungicidal, insecticidal, bactericidal, herbicidal and antimicrobial, antimalarial agents. They also have applications as dyes, lubricants, and analytical reagents. Hence, the group of 1,3,5-triazine derivatives has developed over the years. Triazine is not only the core amongst them, but is also a factor increasing the kinetic potential of the entire derivatives. Modifying the structure and introducing new substituents makes it possible to obtain compounds with broad inhibitory activity on processes such as proliferation. In some cases, s-triazine derivatives induce cell apoptosis. In this review we will present currently investigated 1,3,5-triazine derivatives with anti-cancer activities, with particular emphasis on their inhibition of enzymes involved in the process of tumorigenesis.<\/jats:p>","DOI":"10.3390\/ph15020221","type":"journal-article","created":{"date-parts":[[2022,2,13]],"date-time":"2022-02-13T20:34:45Z","timestamp":1644784485000},"page":"221","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Recent Advances in the Biological Activity of s-Triazine Core Compounds"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8407-081X","authenticated-orcid":false,"given":"Dawid","family":"Maliszewski","sequence":"first","affiliation":[{"name":"Department of Organic Chemistry, Medical University of Bialystok, 15-222 Bia\u0142ystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3479-0480","authenticated-orcid":false,"given":"Danuta","family":"Drozdowska","sequence":"additional","affiliation":[{"name":"Department of Organic Chemistry, Medical University of Bialystok, 15-222 Bia\u0142ystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,12]]},"reference":[{"key":"ref_1","unstructured":"WHO, Regional Office for Europe (2020). World Cancer Report: Cancer Research for Cancer Development, IARC."},{"key":"ref_2","first-page":"36","article-title":"Present and Future Prospect of Small Molecule & Related Targeted Therapy Against Human Cancer","volume":"9","author":"Pathak","year":"2018","journal-title":"Vivechan Int. J. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1016\/j.bmc.2015.06.049","article-title":"4,6-Substituted-1,3,5-Triazin-2(1H)-Ones as Monocyclic Catalytic Inhibitors of Human DNA Topoisomerase II\u03b1 Targeting the ATP Binding Site","volume":"23","author":"Gobec","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"103525","DOI":"10.1016\/j.bioorg.2019.103525","article-title":"Design, Synthesis and Biological Evaluation of Substituted 2-(Thiophen-2-Yl)-1,3,5-Triazine Derivatives as Potential Dual PI3K\u03b1\/MTOR Inhibitors","volume":"95","author":"Zhang","year":"2020","journal-title":"Bioorg. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"115997","DOI":"10.1016\/j.bmc.2021.115997","article-title":"Discovery of Novel 1,3,5-Triazine Derivatives as Potent Inhibitor of Cervical Cancer via Dual Inhibition of PI3K\/MTOR","volume":"32","author":"Hu","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bmcl.2015.11.083","article-title":"Synthesis, in Vitro Antitumor Activity, Dihydrofolate Reductase Inhibition, DNA Intercalation and Structure\u2013Activity Relationship Studies of 1,3,5-Triazine Analogues","volume":"26","author":"Singla","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.ejmech.2016.11.010","article-title":"Design, Synthesis, Docking Studies and Biological Evaluation of Novel Dihydro-1,3,5-Triazines as Human DHFR Inhibitors","volume":"125","author":"Zhou","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1021\/acs.jmedchem.6b01253","article-title":"Design, Synthesis, and Biological Evaluation of Coupled Bioactive Scaffolds as Potential Anticancer Agents for Dual Targeting of Dihydrofolate Reductase and Thioredoxin Reductase","volume":"60","author":"Ng","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.ejmech.2017.11.005","article-title":"Novel 2-(2-Arylmethylthio-4-Chloro-5-Methylbenzenesulfonyl)-1-(1,3,5-Triazin-2-Ylamino) Guanidine Derivatives: Inhibition of Human Carbonic Anhydrase Cytosolic Isozymes I and II and the Transmembrane Tumor-Associated Isozymes IX and XII, Anticancer Activity, and Molecular Modeling Studies","volume":"143","author":"Angeli","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bioorg.2017.12.034","article-title":"Novel Sulfonamide Incorporating Piperazine, Aminoalcohol and 1,3,5-Triazine Structural Motifs with Carbonic Anhydrase I, II and IX Inhibitory Action","volume":"77","author":"Vullo","year":"2018","journal-title":"Bioorg. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bioorg.2018.10.005","article-title":"Design, Synthesis and Biological Evaluation of Novel Ureido Benzenesulfonamides Incorporating 1,3,5-Triazine Moieties as Potent Carbonic Anhydrase IX Inhibitors","volume":"82","author":"Lolak","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.bmc.2019.03.001","article-title":"Discovery of New Ureido Benzenesulfonamides Incorporating 1,3,5-Triazine Moieties as Carbonic Anhydrase I, II, IX and XII Inhibitors","volume":"27","author":"Lolak","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5851","DOI":"10.1038\/s41598-017-05934-5","article-title":"Design and Discovery of Novel Monastrol-1,3,5-Triazines as Potent Anti-Breast Cancer Agent via Attenuating Epidermal Growth Factor Receptor Tyrosine Kinase","volume":"7","author":"Srivastava","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_14","first-page":"4175","article-title":"Anti-breast Cancer Activity of Selected 1,3,5-triazines via Modulation of EGFR-TK","volume":"18","author":"Yan","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/jhet.3791","article-title":"Design, Synthesis, Anticancer, Antibacterial, and Antifungal Evaluation of 4-aminoquinoline-1,3,5-triazine Derivatives","volume":"57","author":"Bhat","year":"2020","journal-title":"J. Heterocycl. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1021\/jm500784e","article-title":"Design, Synthesis, and Evaluation of Novel Imidazo[1,2-a][1,3,5] Triazines and Their Derivatives as Focal Adhesion Kinase Inhibitors with Antitumor Activity","volume":"58","author":"Dao","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1016\/j.bmcl.2016.02.085","article-title":"Synthesis and in Vitro Anticancer Evaluation of Some 4,6-Diamino-1,3,5-Triazine-2-Carbohydrazides as Rad6 Ubiquitin Conjugating Enzyme Inhibitors","volume":"26","author":"Kothayer","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1071\/CH16006","article-title":"Anticancer Evaluation of Tris (Triazolyl)Triazine Derivatives Generated via Click Chemistry","volume":"69","author":"Nour","year":"2016","journal-title":"Aust. J. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1007\/s00044-015-1430-9","article-title":"Synthesis and Characterization of New S-Triazine Bearing Benzimidazole and Benzothiazole Derivatives as Anticancer Agents","volume":"24","author":"Kumar","year":"2015","journal-title":"Med. Chem. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.bioorg.2019.03.063","article-title":"Design and Synthesis of Mono-and Di-Pyrazolyl-s-Triazine Derivatives, Their Anticancer Profile in Human Cancer Cell Lines, and in Vivo Toxicity in Zebrafish Embryos","volume":"87","author":"Farooq","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Malebari, A.M., Abd Alhameed, R., Almarhoon, Z., Farooq, M., Wadaan, M.A.M., Sharma, A., de la Torre, B.G., Albericio, F., and El-Faham, A. (2021). The Antiproliferative and Apoptotic Effect of a Novel Synthesized S-Triazine Dipeptide Series, and Toxicity Screening in Zebrafish Embryos. Molecules, 26.","DOI":"10.3390\/molecules26041170"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejmech.2016.03.088","article-title":"Synthesis and in Vitro Evaluation of Novel Triazine Analogues as Anticancer Agents and Their Interaction Studies with Bovine Serum Albumin","volume":"117","author":"Singla","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Smolnikov, S., Gorgopina, E., Lezhnyova, V., Ong, G., Chui, W.-K., and Dolzhenko, A. (2017). 4-Phenethylthio-2-Phenylpyrazolo[1,5-a][1,3,5]Triazin-7(6H)-One. Molbank, 2017.","DOI":"10.3390\/M970"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Makowska, A., S\u0105czewski, F., Bednarski, P., S\u0105czewski, J., and Balewski, \u0141. (2018). Hybrid Molecules Composed of 2,4-Diamino-1,3,5-Triazines and 2-Imino-Coumarins and Coumarins. Synthesis and Cytotoxic Properties. Molecules, 23.","DOI":"10.3390\/molecules23071616"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Moreno, L., Quiroga, J., Abonia, R., Ram\u00edrez-Prada, J., and Insuasty, B. (2018). Synthesis of New 1,3,5-Triazine-Based 2-Pyrazolines as Potential Anticancer Agents. Molecules, 23.","DOI":"10.3390\/molecules23081956"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/cbdd.13133","article-title":"Novel 1,3,5-Triazine Derivatives Exert Potent Anti-Cervical Cancer Effects by Modulating Bax, Bcl2 and Caspases Expression","volume":"91","author":"Wang","year":"2018","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/open.201800136","article-title":"Design and Synthesis of New 1,3,5-Trisubstituted Triazines for the Treatment of Cancer and Inflammation","volume":"7","author":"Zacharie","year":"2018","journal-title":"ChemistryOpen"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1021\/acscombsci.9b00079","article-title":"New One-Pot Synthesis of 1,3,5-Triazines: Three-Component Condensation, Dimroth Rearrangement, and Dehydrogenative Aromatization","volume":"21","author":"Junaid","year":"2019","journal-title":"ACS Comb. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"12135","DOI":"10.1039\/D0RA00643B","article-title":"6, N 2 -Diaryl-1,3,5-Triazine-2,4-Diamines: Synthesis, Antiproliferative Activity and 3D-QSAR Modeling","volume":"10","author":"Junaid","year":"2020","journal-title":"RSC Adv."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"25517","DOI":"10.1039\/D0RA04970K","article-title":"Design, Synthesis, and Biological Evaluation of New 6, N 2 -Diaryl-1,3,5-Triazine-2,4-Diamines as Anticancer Agents Selectively Targeting Triple Negative Breast Cancer Cells","volume":"10","author":"Junaid","year":"2020","journal-title":"RSC Adv."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1900053","DOI":"10.1002\/ardp.201900053","article-title":"Quinazoline Based 1,3,5-triazine Derivatives as Cancer Inhibitors by Impeding the Phosphorylated RET Tyrosine Kinase Pathway: Design, Synthesis, Docking, and QSAR Study","volume":"352","author":"Pathak","year":"2019","journal-title":"Arch. Pharm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1007\/s10637-018-0712-8","article-title":"The Cellular Effects of Novel Triazine Nitrogen Mustards in Glioblastoma LBC3, LN-18 and LN-229 Cell Lines","volume":"37","author":"Drozdowska","year":"2019","journal-title":"Investig. New Drugs"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1007\/s10637-019-00838-9","article-title":"Synthesis and Cellular Effects of Novel 1,3,5-Triazine Derivatives in DLD and Ht-29 Human Colon Cancer Cell Lines","volume":"38","author":"Hermanowicz","year":"2020","journal-title":"Investng. New Drugs"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"103239","DOI":"10.1016\/j.bioorg.2019.103239","article-title":"Design, Synthesis and Molecular Docking of Novel Pyrazolo[1,5-a][1,3,5]Triazine Derivatives as CDK2 Inhibitors","volume":"92","author":"Oudah","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_35","first-page":"1860","article-title":"Synthesis, Molecular Modelling and Anticancer Activities of New Molecular Hybrids Containing 1,4-Naphthoquinone, 7-Chloroquinoline, 1,3,5-Triazine and Morpholine Cores as PI3K and AMPK Inhibitors in the Metastatic Melanoma Cells","volume":"30","author":"Fiorot","year":"2019","journal-title":"J. Braz. Chem. Soc."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"60","DOI":"10.7124\/bc.000A21","article-title":"2-(Dichloromethyl)Pyrazolo[1,5-a][1,3,5]Triazines: Synthesis and Anticancer Activity","volume":"36","author":"Velihina","year":"2020","journal-title":"Biopolym. Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"030006052090387","DOI":"10.1177\/0300060520903874","article-title":"Preparation and Antitumor Effects of 4-Amino-1,2,4-Triazole Schiff Base Derivative","volume":"48","author":"Jiang","year":"2020","journal-title":"J. Int. Med. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"34114","DOI":"10.1039\/D0RA06799G","article-title":"Synthesis, Biological Evaluation, and in Silico Studies of Novel Chalcone- and Pyrazoline-Based 1,3,5-Triazines as Potential Anticancer Agents","volume":"10","author":"Moreno","year":"2020","journal-title":"RSC Adv."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev.biochem.70.1.369","article-title":"DNA Topoisomerases: Structure, Function, and Mechanism","volume":"70","author":"Champoux","year":"2001","journal-title":"Annu. Rev. Biochem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"13541","DOI":"10.1074\/jbc.M116.772426","article-title":"Kinetic and Structural Analyses Reveal Residues in Phosphoinositide 3-Kinase \u03b1 That Are Critical for Catalysis and Substrate Recognition","volume":"292","author":"Maheshwari","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13045-019-0754-1","article-title":"Targeting MTOR for Cancer Therapy","volume":"12","author":"Hua","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Tarantelli, C., Lupia, A., Stathis, A., and Bertoni, F. (2020). Is There a Role for Dual PI3K\/MTOR Inhibitors for Patients Affected with Lymphoma?. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21031060"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"9846","DOI":"10.1021\/bi010621k","article-title":"Backbone Dynamics in Dihydrofolate Reductase Complexes: Role of Loop Flexibility in the Catalytic Mechanism","volume":"40","author":"Osborne","year":"2001","journal-title":"Biochemistry"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"910","DOI":"10.2174\/0929867326666191016151018","article-title":"Recent Design and Structure-Activity Relationship Studies on the Modifications of DHFR Inhibitors as Anticancer Agents","volume":"28","author":"Drozdowska","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.bmc.2015.03.012","article-title":"Triazine\u2013Benzimidazole Hybrids: Anticancer Activity, DNA Interaction and Dihydrofolate Reductase Inhibitors","volume":"23","author":"Singla","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/med.10025","article-title":"Carbonic Anhydrase Inhibitors","volume":"23","author":"Supuran","year":"2003","journal-title":"Med. Res. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.humpath.2009.05.010","article-title":"Growth Factor Receptor Expression in Anal Squamous Lesions: Modifications Associated with Oncogenic Human Papillomavirus and Human Immunodeficiency Virus","volume":"40","author":"Walker","year":"2009","journal-title":"Hum. Pathol."},{"key":"ref_48","unstructured":"Kumar, V., Abbas, A.K., Aster, J.C., and Robbins, S.L. (2013). Robbins Basic Pathology, Saunders. [9th ed.]."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.mce.2014.08.001","article-title":"Oxygen Sensing and Metabolic Homeostasis","volume":"397","author":"Palmer","year":"2014","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1038\/sj.onc.1203855","article-title":"Vascular Endothelial Growth Factor Receptors in the Regulation of Angiogenesis and Lymphangiogenesis","volume":"19","author":"Karkkainen","year":"2000","journal-title":"Oncogene"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"7192","DOI":"10.1073\/pnas.94.14.7192","article-title":"Vascular Endothelial Growth Factor: Crystal Structure and Functional Mapping of the Kinase Domain Receptor Binding Site","volume":"94","author":"Muller","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s10787-018-0471-3","article-title":"Quinazoline Clubbed 1,3,5-Triazine Derivatives as VEGFR2 Kinase Inhibitors: Design, Synthesis, Docking, in Vitro Cytotoxicity and in Ovo Antiangiogenic Activity","volume":"26","author":"Pathak","year":"2018","journal-title":"Inflammopharmacology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nrc1886","article-title":"Metastasis: A Question of Life or Death","volume":"6","author":"Mehlen","year":"2006","journal-title":"Nat. Rev. Cancer"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/2\/221\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:18:30Z","timestamp":1760134710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/2\/221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,12]]},"references-count":53,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["ph15020221"],"URL":"https:\/\/doi.org\/10.3390\/ph15020221","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,12]]}}}